Effects of dipotassium-trioxohydroxytetrafluorotriborate, K2[B3O3F4OH], on cell viability and gene expression of common human cancer drug targets in a melanoma cell line. (1st November 2016)

• Record Type: Journal Article
• Authors: Pojskic, Lejla; Haveric, Sanin; Lojo-Kadric, Naida; Hadzic, Maida; Haveric, Anja; Galic, Zoran; Galic, Borivoj; Vullo, Daniela; Supuran, Claudiu T.; Milos, Mladen
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 31:Number 6(2016:Dec.)
• Page Start: 999
• Page End: 1004
• Publication Date: 2016-11-01
• Subjects: Antitumor drug target -- dipotassium-trioxohydroxytetrafluorotriborate -- gene down-regulation -- gene expression -- human melanoma cell line -- human telomerase -- insulin-like growth factor 1; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.3109/14756366.2015.1078329
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: Recently it was found that dipotassium-trioxohydroxytetrafluorotriborate, K2 (B3 O3 F4 OH), is a potent and highly specific inhibitor of precancerous cell processes. We conducted gene expression profiling of human melanoma cells before and after treatment with two concentrations (0.1 and 1 mM) of this boron inorganic derivative in order to assess its effects on deregulation of genes associated with tumor pathways. Parallel trypan blue exclusion assay was performed to assess the cytotoxicity effects of this chemical. Treatment with K2 (B3 O3 F4 OH) induced a significant decrease of cell viability in melanoma cellline at both tested concentrations. Furthermore, these treatments caused deregulation of more than 30 genes known as common anti-tumor drug targets. IGF-1 and hTERT were found to be significantly downregulated and this result may imply potential use of K2 (B3 O3 F4 OH) as an inhibitor or human telomerase and insulin-like growth factor 1, both of which are associated with various tumor pathways.